Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study

• Novo Nordisk (NYSE:NVO) reported that its late stage ZEUS trial of ziltivekimab in patients with atherosclerotic cardiovascular disease and chronic kidney disease did not show a statistically significant clinical benefit.
• The company said the trial still showed evidence of biological target engagement but will book a non cash impairment linked to the asset.
• Novo Nordisk confirmed that it plans to continue its research efforts in cardiovascular disease despite the ZEUS outcome.

Novo Nordisk, best known for its diabetes and obesity treatments, has been working to widen its focus into cardiovascular disease. The ZEUS result highlights the uncertainty around that effort at a time when large drug makers are seeking broader uses for cardiometabolic therapies. For investors following NYSE:NVO, this update adds a fresh data point to an already active research pipeline.

The company has said it remains committed to cardiovascular research, with other trials still underway. Readers watching Novo Nordisk can now consider this trial setback alongside the long term potential the company identifies in cardiometabolic medicine, especially beyond its core diabetes and obesity drugs.

Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.

We've flagged 4 risks for Novo Nordisk. See which could impact your investment.

The ZEUS outcome removes one potential future product from Novo Nordisk’s cardiometabolic line up and shows how clinically complex the cardiovascular disease market is. Ziltivekimab engaged its intended IL 6 target and affected biological markers, yet this did not translate into fewer major cardiovascular events for patients. For investors, this underlines that moving from mechanistic promise to hard outcomes can be a high bar, especially in indications already served by entrenched therapies from peers such as Eli Lilly and AstraZeneca. Novo Nordisk will take a non cash impairment on the asset, although the company has indicated that this charge is already incorporated into guidance and does not change its 2026 operating profit outlook. The trial result therefore looks more like a setback for pipeline optionality in cardiovascular disease than a shift in the near term financial picture. With HERMES and ARTEMIS still in progress and results expected in early 2027, Novo Nordisk continues to pursue a broader cardiometabolic footprint. Readers can weigh this news as one data point in assessing how diversified future revenue sources could become beyond diabetes and obesity treatments.

The Risks and Rewards Investors Should Consider

• ⚠️ The ZEUS failure highlights clinical risk in Novo Nordisk’s cardiovascular pipeline, which could limit how much of its future revenue mix comes from beyond diabetes and obesity treatments.
• ⚠️ The non cash impairment on ziltivekimab adds to concerns already flagged about non cash earnings and may increase scrutiny of how much profit comes from accounting items rather than core cash generation.
• 🎁 Novo Nordisk has confirmed that the impairment does not change its 2026 operating profit outlook, which signals that existing products are expected to continue supporting the current guidance framework.
• 🎁 The company still has two large cardiovascular outcome studies, HERMES and ARTEMIS, running through to early 2027, which keeps the opportunity for additional cardiometabolic indications on the table.

What To Watch Going Forward

From here, readers watching Novo Nordisk may want to track three things. First, any detailed data releases from ZEUS that clarify why biological target engagement did not convert into better clinical outcomes. Second, updates on the design, timelines, or any interim information for HERMES and ARTEMIS, since these now carry more weight for the company’s cardiovascular ambitions. Third, any changes in how competitors like Eli Lilly or AstraZeneca position their own cardiometabolic drugs, especially if they refer to inflammation pathways similar to IL 6. Together, these signals can help you judge whether ZEUS was a one off setback in an otherwise broad research effort or a sign that this specific pathway is less commercially promising than hoped in cardiovascular disease.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com